

# SAFETY DATA SHEET



Revision date: 02-Oct-2013

Version: 2.0

Page 1 of 11

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Rimadyl®(Carprofen) Injectable Solution

**Trade Name:** Rimadyl  
**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Veterinary product used as non-steroidal, anti-inflammatory drug (nsaid)  
**Restrictions on Use:** Not for human use

### Details of the Supplier of the Safety Data Sheet

Zoetis Inc.  
100 Campus Drive, P.O. Box 651  
Florham Park, New Jersey 07932 (USA)  
Rocky Mountain Poison Control Center Phone: 1-866-531-8896  
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.  
Mercuriusstraat 20  
1930 Zaventem  
Belgium

**Emergency telephone number:**  
**CHEMTREC (24 hours):** 1-800-424-9300  
**Contact E-Mail:** VMIPSrecords@zoetis.com

**Emergency telephone number:**  
**International CHEMTREC (24 hours):** +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

**Appearance:** Clear, colorless to pale yellow liquid

### Classification of the Substance or Mixture

#### GHS - Classification

Reproductive Toxicity: Category 2  
Specific target organ systemic toxicity (repeated exposure): Category 2

#### US OSHA Specific - Classification

#### EU Classification:

EU Indication of danger: Harmful  
Toxic to Reproduction: Category 3

EU Symbol: Xn

EU Risk Phrases:  
R22 - Harmful if swallowed.  
R63 - Possible risk of harm to the unborn child.

### Label Elements

**Signal Word:** Warning

**Hazard Statements:**  
H361 - Suspected of damaging fertility or the unborn child  
H373 - May cause damage to organs through prolonged or repeated exposure

## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 2 of 11  
Version: 2.0

### Precautionary Statements:

P201 - Obtain special instructions before use  
P202 - Do not handle until all safety precautions have been read and understood  
P260 - Do not breathe dust/fume/gas/mist/vapors/spray  
P280 - Wear protective gloves/protective clothing/eye protection/face protection  
P308 + P313 - IF exposed or concerned: Get medical attention/advice  
P405 - Store locked up



### Other Hazards

#### Short Term:

There have been anecdotal reports that workers handling this material have experienced skin irritation and/or sensitivity reactions.

#### Long Term:

Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system, the developing fetus.  
Hazardous Substance. Non-Dangerous Goods.

### Australian Hazard Classification (NOHSC):

#### Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

### Hazardous

| Ingredient        | CAS Number | EU EINECS/ELINCS List | EU Classification                    | GHS Classification  | %  |
|-------------------|------------|-----------------------|--------------------------------------|---|----|
| Glycocholic acid  | 475-31-0   | 207-494-9             | Not Listed                           | Not Listed  | *  |
| Benzyl Alcohol    | 100-51-6   | 202-859-9             | Xn; R20/22                           | Acute Tox. 4 (H302)<br>Acute Tox. 4 (H332)                                    | *  |
| Hydrogen chloride | 7647-01-0  | 231-595-7             | T; R23<br>C; R35                     | STOT SE 3 (H335)<br>Skin Corr. 1A (H314)<br>Press. Gas<br>Acute Tox. 3 (H331) | ** |
| Sodium hydroxide  | 1310-73-2  | 215-185-5             | C; R35                               | Skin Corr. 1A (H314)  | ** |
| Carprofen         | 53716-49-7 | 258-712-4             | Repr.Cat.3;R63<br>T;R25<br>Xn;R48/22 | Acute Tox 3 (H301)<br>Repro 2 (H361d)<br>STOT Re 2 (H373)                     | 5  |

| Ingredient | CAS Number | EU EINECS/ELINCS List | EU Classification | GHS Classification | % |
|------------|------------|-----------------------|-------------------|--------------------|---|
|------------|------------|-----------------------|-------------------|--------------------|---|

## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 3 of 11  
Version: 2.0

|                     |           |           |            |            |   |
|---------------------|-----------|-----------|------------|------------|---|
| Lecithin            | 8002-43-5 | 232-307-2 | Not Listed | Not Listed | * |
| Water for injection | 7732-18-5 | 231-791-2 | Not Listed | Not Listed | * |

**Additional Information:**

\* Proprietary

\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:**

Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

**Skin Contact:**

Remove contaminated clothing and shoes. Wash skin with soap and water. If irritation occurs or persists, get medical attention.

**Ingestion:**

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**

Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

**Symptoms and Effects of Exposure:**

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions**

None known

**Aggravated by Exposure:**

**Indication of the Immediate Medical Attention and Special Treatment Needed**

**Notes to Physician:**

None

### 5. FIRE-FIGHTING MEASURES

**Extinguishing Media:**

Use carbon dioxide, dry chemical, or water spray.

**Special Hazards Arising from the Substance or Mixture**

**Hazardous Combustion**

May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

**Products:**

**Fire / Explosion Hazards:**

Not applicable

**Advice for Fire-Fighters**

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.

### 6. ACCIDENTAL RELEASE MEASURES

**Personal Precautions, Protective Equipment and Emergency Procedures**

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Methods and Material for Containment and Cleaning Up**

## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 4 of 11  
Version: 2.0

**Measures for Cleaning / Collecting:**

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Additional Consideration for Large Spills:**

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

**Precautions for Safe Handling**

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Conditions for Safe Storage, Including any Incompatibilities**

**Storage Conditions:** Store in a cool, dry, well-ventilated area. Store as directed by product packaging.

**Incompatible Materials:** None known

**Specific end use(s):** No data available

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

**Benzyl Alcohol**

|                          |                       |
|--------------------------|-----------------------|
| Bulgaria OEL - TWA       | 5.0 mg/m <sup>3</sup> |
| Czech Republic OEL - TWA | 40 mg/m <sup>3</sup>  |
| Finland OEL - TWA        | 10 ppm                |
|                          | 45 mg/m <sup>3</sup>  |
| Latvia OEL - TWA         | 5 mg/m <sup>3</sup>   |
| Lithuania OEL - TWA      | 5 mg/m <sup>3</sup>   |
| Poland OEL - TWA         | 240 mg/m <sup>3</sup> |

**Hydrogen chloride**

|                                |                       |
|--------------------------------|-----------------------|
| ACGIH Ceiling Threshold Limit: | 2 ppm                 |
| Australia PEAK                 | 5 ppm                 |
|                                | 7.5 mg/m <sup>3</sup> |
| Austria OEL - MAKs             | 5 ppm                 |
|                                | 8 mg/m <sup>3</sup>   |
| Belgium OEL - TWA              | 5 ppm                 |
|                                | 8 mg/m <sup>3</sup>   |
| Bulgaria OEL - TWA             | 8.0 mg/m <sup>3</sup> |
|                                | 5 ppm                 |
| Cyprus OEL - TWA               | 5 ppm                 |
|                                | 8 mg/m <sup>3</sup>   |
| Czech Republic OEL - TWA       | 8 mg/m <sup>3</sup>   |
| Estonia OEL - TWA              | 5 ppm                 |
|                                | 8 mg/m <sup>3</sup>   |
| Germany - TRGS 900 - TWAs      | 2 ppm                 |
|                                | 3 mg/m <sup>3</sup>   |
| Germany (DFG) - MAK            | 2 ppm                 |
|                                | 3.0 mg/m <sup>3</sup> |
| Greece OEL - TWA               | 5 ppm                 |
|                                | 7 mg/m <sup>3</sup>   |

## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 5 of 11  
Version: 2.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

|                                |                        |
|--------------------------------|------------------------|
| Hungary OEL - TWA              | 8 mg/m <sup>3</sup>    |
| Ireland OEL - TWAs             | 5 ppm                  |
|                                | 8 mg/m <sup>3</sup>    |
| Italy OEL - TWA                | 5 ppm                  |
|                                | 8 mg/m <sup>3</sup>    |
| Japan - OELs - Ceilings        | 5 ppm                  |
|                                | 7.5 mg/m <sup>3</sup>  |
| Latvia OEL - TWA               | 5 ppm                  |
|                                | 8 mg/m <sup>3</sup>    |
| Lithuania OEL - TWA            | 5 ppm                  |
|                                | 8 mg/m <sup>3</sup>    |
| Luxembourg OEL - TWA           | 5 ppm                  |
|                                | 8 mg/m <sup>3</sup>    |
| Malta OEL - TWA                | 5 ppm                  |
|                                | 8 mg/m <sup>3</sup>    |
| Netherlands OEL - TWA          | 8 mg/m <sup>3</sup>    |
| Vietnam OEL - TWAs             | 5 mg/m <sup>3</sup>    |
| Poland OEL - TWA               | 5 mg/m <sup>3</sup>    |
| Romania OEL - TWA              | 5 ppm                  |
|                                | 8 mg/m <sup>3</sup>    |
| Slovakia OEL - TWA             | 5 ppm                  |
|                                | 8.0 mg/m <sup>3</sup>  |
| Slovenia OEL - TWA             | 5 ppm                  |
|                                | 8 mg/m <sup>3</sup>    |
| Spain OEL - TWA                | 5 ppm                  |
|                                | 7.6 mg/m <sup>3</sup>  |
| Switzerland OEL -TWAs          | 2 ppm                  |
|                                | 3.0 mg/m <sup>3</sup>  |
| <b>Sodium hydroxide</b>        |                        |
| ACGIH Ceiling Threshold Limit: | 2 mg/m <sup>3</sup>    |
| Australia PEAK                 | 2 mg/m <sup>3</sup>    |
| Austria OEL - MAKs             | 2 mg/m <sup>3</sup>    |
| Bulgaria OEL - TWA             | 2.0 mg/m <sup>3</sup>  |
| Czech Republic OEL - TWA       | 1 mg/m <sup>3</sup>    |
| Estonia OEL - TWA              | 1 mg/m <sup>3</sup>    |
| France OEL - TWA               | 2 mg/m <sup>3</sup>    |
| Greece OEL - TWA               | 2 mg/m <sup>3</sup>    |
| Hungary OEL - TWA              | 2 mg/m <sup>3</sup>    |
| Japan - OELs - Ceilings        | 2 mg/m <sup>3</sup>    |
| Latvia OEL - TWA               | 0.5 mg/m <sup>3</sup>  |
| OSHA - Final PELs - TWAs:      | 2 mg/m <sup>3</sup>    |
| Poland OEL - TWA               | 0.5 mg/m <sup>3</sup>  |
| Slovakia OEL - TWA             | 2 mg/m <sup>3</sup>    |
| Slovenia OEL - TWA             | 2 mg/m <sup>3</sup>    |
| Sweden OEL - TWAs              | 1 mg/m <sup>3</sup>    |
| Switzerland OEL -TWAs          | 2 mg/m <sup>3</sup>    |
| <b>Carprofen</b>               |                        |
| Zoetis OEL TWA 8-hr            | 1000 µg/m <sup>3</sup> |

Exposure Controls

## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 6 of 11  
Version: 2.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

|                                       |  |
|---------------------------------------|--|
| <b>Engineering Controls:</b>          | Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. |
| <b>Personal Protective Equipment:</b> | Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).  |
| <b>Hands:</b>                         | Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.  |
| <b>Eyes:</b>                          | Wear safety glasses or goggles if eye contact is possible.   |
| <b>Skin:</b>                          | Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.  |
| <b>Respiratory protection:</b>        | None required under normal conditions of use. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.   |

### 9. PHYSICAL AND CHEMICAL PROPERTIES

|   |                    |                          |                                 |
|---|--------------------|--------------------------|---------------------------------|
| <b>Physical State:</b>                                      | Liquid             | <b>Color:</b>            | Clear, colorless to pale yellow |
| <b>Odor:</b>  | No data available. | <b>Odor Threshold:</b>   | No data available.              |
| <b>Molecular Formula:</b>                                   | Mixture            | <b>Molecular Weight:</b> | Mixture                         |
| <b>Solvent Solubility:</b>                                  | No data available  |                          |                                 |
| <b>Water Solubility:</b>                                    | No data available  |                          |                                 |
| <b>pH:</b>  | 7.0-7.4            |                          |                                 |
| <b>Melting/Freezing Point (°C):</b>                         | No data available  |                          |                                 |
| <b>Boiling Point (°C):</b>                                  | No data available. |                          |                                 |
| <b>Partition Coefficient: (Method, pH, Endpoint, Value)</b> | No data available  |                          |                                 |
| <b>Decomposition Temperature (°C):</b>                      | No data available. |                          |                                 |
| <b>Evaporation Rate (Gram/s):</b>                           | No data available  |                          |                                 |
| <b>Vapor Pressure (kPa):</b>                                | No data available  |                          |                                 |
| <b>Vapor Density (g/ml):</b>                                | No data available  |                          |                                 |
| <b>Relative Density:</b>                                    | No data available  |                          |                                 |
| <b>Viscosity:</b>   | No data available  |                          |                                 |
| <b>Flammability:</b>  |                    |                          |                                 |
| <b>Autoignition Temperature (Solid) (°C):</b>               | No data available  |                          |                                 |
| <b>Flammability (Solids):</b>                               | No data available  |                          |                                 |
| <b>Flash Point (Liquid) (°C):</b>                           | No data available  |                          |                                 |
| <b>Upper Explosive Limits (Liquid) (% by Vol.):</b>         | No data available  |                          |                                 |
| <b>Lower Explosive Limits (Liquid) (% by Vol.):</b>         | No data available  |                          |                                 |
| <b>Polymerization:</b>                                      | Will not occur     |                          |                                 |

### 10. STABILITY AND REACTIVITY

|   |  |
|---|--|
| <b>Reactivity:</b>                        | No data available                      |
| <b>Chemical Stability:</b>                | Stable under normal conditions of use. |
| <b>Possibility of Hazardous Reactions</b> |  |
| <b>Oxidizing Properties:</b>              | None                                   |
| <b>Conditions to Avoid:</b>               | None known                             |
| <b>Incompatible Materials:</b>            | None known                             |

## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 7 of 11  
Version: 2.0

### 10. STABILITY AND REACTIVITY

#### Hazardous Decomposition Products:

Thermal decomposition products may include carbon monoxide, carbon dioxide, oxides of nitrogen and hydrogen chloride.

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

##### General Information:

The information included in this section describes the potential hazards of the individual ingredients.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Carprofen

Mouse Oral LD50 282 mg/kg  
Rat Oral LD50 149mg/kg  
Rat (M/F) SC LD50 230/190mg/kg  
Rat (M/F) IP LD50 140/110 mg/kg

##### Lecithin

Rat Oral LD50 > 8 ml/kg

##### Benzyl Alcohol

Rat Oral LD50 1230 mg/kg  
Rat Para-periosteal LD50 53mg/kg  
  
Rat Inhalation LC50 >4.178mg/L

##### Sodium hydroxide

Mouse IP LD50 40 mg/kg

##### Hydrogen chloride

Rat Sub-tenon injection (eye) LC50 1H 3,124 ppm  
Mouse Inhalation LC50 1H 1,108ppm  
Mouse Oral LD50 900mg/kg

##### Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Carprofen

Eye Irritation Rabbit Non-irritating  
Skin Irritation Rabbit Non-irritating  
Skin Sensitization - GPMT Guinea Pig Negative  
Antigenicity- Delayed skin reaction Guinea Pig No effect

##### Benzyl Alcohol

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Moderate  
Skin Irritation Guinea Pig Moderate

##### Sodium hydroxide

Eye Irritation Rabbit Severe

## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 8 of 11  
Version: 2.0

### 11. TOXICOLOGICAL INFORMATION

Skin Irritation Rabbit Severe

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### **Carprofen**

|            |     |                  |       |                         |
|------------|-----|------------------|-------|-------------------------|
| 13 Week(s) | Rat | Oral 5 mg/kg/day | NOAEL | Gastrointestinal System |
| 13 Week(s) | Dog | Oral 5 mg/kg/day | NOAEL | None identified         |

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### **Carprofen**

|                                  |        |                  |       |   |
|----------------------------------|--------|------------------|-------|---|
| Reproductive & Fertility         | Rat    | 20 mg/kg/day     | NOAEL | Fetotoxicity, Maternal toxicity             |
| Embryo / Fetal Development       | Rat    | 20 mg/kg/day     | NOAEL | Not Teratogenic                             |
| Prenatal & Postnatal Development | Mouse  | 40 mg/kg/day     | NOAEL | Not Teratogenic                             |
| Prenatal & Postnatal Development | Rabbit | Oral 6 mg/kg/day | NOAEL | Embryotoxicity, Early embryonic development |

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### **Carprofen**

|                               |                   |          |
|-------------------------------|-------------------|----------|
| Bacterial Mutagenicity (Ames) | <i>Salmonella</i> | Negative |
| <i>In Vivo</i> Micronucleus   | Mouse             | Negative |

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### **Carprofen**

|           |     |                   |       |  |
|-----------|-----|-------------------|-------|--|
| 2 Year(s) | Rat | Oral 10 mg/kg/day | NOAEL | Not carcinogenic, Gastrointestinal system    |
| 2 Year(s) | Dog | Oral 25 mg/kg/day | NOAEL | Not carcinogenic, No effects at maximum dose |

#### Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.  
See below

#### **Hydrogen chloride**

##### **IARC:**

Group 3 (Not Classifiable)

### 12. ECOLOGICAL INFORMATION

#### **Environmental Overview:**

The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

#### **Toxicity:**

No data available

#### **Persistence and Degradability:**

No data available

#### **Bio-accumulative Potential:**

No data available

#### **Mobility in Soil:**

No data available



## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 9 of 11  
Version: 2.0

### 13. DISPOSAL CONSIDERATIONS

#### Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Canada - WHMIS: Classifications

##### WHMIS hazard class:

Class D, Division 2, Subdivision A



#### Glycocholic acid

|                                    |            |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65          | Not Listed |
| EU EINECS/ELINCS List              | 207-494-9  |

#### Benzyl Alcohol

|   |            |
|---|------------|
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present    |
| Australia (AICS):                           | Present    |
| EU EINECS/ELINCS List                       | 202-859-9  |

#### Lecithin

|   |            |
|---|------------|
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present    |
| Australia (AICS):                           | Present    |

## SAFETY DATA SHEET

Material Name: Rimadyl®(Carprofen) Injectable Solution  
Revision date: 02-Oct-2013

Page 10 of 11  
Version: 2.0

### 15. REGULATORY INFORMATION

|   |           |
|---|-----------|
| REACH - Annex IV - Exemptions from the obligations of Register: | Present   |
| EU EINECS/ELINCS List   | 232-307-2 |

#### Water for injection

|   |            |
|---|------------|
| CERCLA/SARA 313 Emission reporting                              | Not Listed |
| California Proposition 65                                       | Not Listed |
| Inventory - United States TSCA - Sect. 8(b)                     | Present    |
| Australia (AICS):   | Present    |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present    |
| EU EINECS/ELINCS List   | 231-791-2  |

#### Hydrogen chloride

|  |            |
|--|------------|
| CERCLA/SARA 313 Emission reporting                                 | 1.0 %      |
| CERCLA/SARA Hazardous Substances and their Reportable Quantities:  | 5000 lb    |
|  | 2270 kg    |
| CERCLA/SARA - Section 302 Extremely Hazardous TPQs                 | 500 lb     |
| CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs | 5000 lb    |
| California Proposition 65  | Not Listed |
| Inventory - United States TSCA - Sect. 8(b)                        | Present    |
| Australia (AICS):  | Present    |
| Standard for the Uniform Scheduling for Drugs and Poisons:         | Schedule 5 |
|  | Schedule 6 |
| EU EINECS/ELINCS List  | 231-595-7  |

#### Sodium hydroxide

|   |            |
|---|------------|
| CERCLA/SARA 313 Emission reporting                                | Not Listed |
| CERCLA/SARA Hazardous Substances and their Reportable Quantities: | 1000 lb    |
|   | 454 kg     |
| California Proposition 65   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b)                       | Present    |
| Australia (AICS):   | Present    |
| Standard for the Uniform Scheduling for Drugs and Poisons:        | Schedule 5 |
|   | Schedule 6 |
| EU EINECS/ELINCS List   | 215-185-5  |

#### Carprofen

|  |            |
|--|------------|
| CERCLA/SARA 313 Emission reporting                         | Not Listed |
| California Proposition 65                                  | Not Listed |
| Australia (AICS):  | Present    |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 4 |
| EU EINECS/ELINCS List                                      | 258-712-4  |

### 16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

## SAFETY DATA SHEET

**Material Name:** Rimadyl®(Carprofen) Injectable Solution  
**Revision date:** 02-Oct-2013

**Page 11 of 11**  
**Version: 2.0**

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed  
Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed  
Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled  
Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled  
Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child  
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure  
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation  
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage

C - Corrosive  
Toxic to Reproduction: Category 3  
T - Toxic  
Xn - Harmful

R23 - Toxic by inhalation.  
R25 - Toxic if swallowed.  
R35 - Causes severe burns.  
R63 - Possible risk of harm to the unborn child.  
R20/22 - Harmful by inhalation and if swallowed.  
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

**Data Sources:** The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

**Reasons for Revision:** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.  
Updated Section 2 - Hazard Identification. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

**Prepared by:** Toxicology and Hazard Communication  
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**